The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines?
The pneumococcal antigens contained in the polysaccharide (PPV23) and conjugate (7-valent, PCV7; 13-valent, PCV13) vaccines have been chosen since they represent the serotypes that more frequently cause invasive pneumococcal disease. Whether these vaccines cover the serotypes most frequently isolated in haematology patients is unclear. The serotype distribution among Streptococcus pneumoniae in 25 consecutive pneumococcal infections that occurred over the last 3 years in two French haematology departments was investigated. The pneumococcal vaccines PCV7, PCV13 and PPV23 were found to cover 76, 84 and 92%, respectively, of the serotypes found.
Debbache
K
K
Haematology Department, Henri Mondor Teaching Hospital, Assistance Publique-Hôpitaux de Paris, and Paris 12 University, Créteil, France.
Varon
E
E
Hicheri
Y
Y
Legrand
P
P
Donay
J-L
JL
Ribaud
P
P
Cordonnier
C
C
D000328:Adult; D000368:Aged; D005260:Female; D005602:France / Q000453:epidemiology; D019337:Hematologic Neoplasms / Q000150:complications / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000453:epidemiology*; D022242:Pneumococcal Vaccines / Q000276:immunology*; D012703:Serotyping; D033581:Stem Cell Transplantation / Q000009:adverse effects; D013296:Streptococcus pneumoniae / Q000145:classification* / Q000302:isolation & purification
D022242:Pneumococcal Vaccines